CAS 58-28-6|Desipramine hydrochloride
Introduction：Basic information about CAS 58-28-6|Desipramine hydrochloride, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Desipramine hydrochloride | ||
|---|---|---|---|
| CAS Number | 58-28-6 | Molecular Weight | 302.842 |
| Density | / | Boiling Point | 407.4ºC at 760 mmHg |
| Molecular Formula | C18H23ClN2 | Melting Point | 214-216ºC |
| MSDS | ChineseUSA | Flash Point | 160.5ºC |
| Symbol | GHS02, GHS06, GHS08 | Signal Word | Danger |
Names
| Name | desipramine hydrochloride |
|---|---|
| Synonym | More Synonyms |
Desipramine hydrochloride BiologicalActivity
| Description | Desipramine hydrochloride is an inhibitor of norepinephrine transporter (NET), 5-HT transporter (SERT) and dopamine transporter (DAT) with Kis of 4, 61 and 78,720 nM, respectively. |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>5-HT ReceptorSignaling Pathways >>Neuronal Signaling >>5-HT ReceptorSignaling Pathways >>Neuronal Signaling >>Dopamine TransporterResearch Areas >>Neurological Disease |
| Target | Ki: 4 nM (NET), 61 nM (SERT), 78720 nM (DAT)[1] |
| In Vivo | Treatment of rats with Desipramine hydrochloride for 14 days reduces norepinephrine transporter (NET) expression in a dose-dependent manner, as indicated by a reduction of the specific binding of 3H-nisoxetine to the NET in preparations of cerebral cortex (F(3,16)=4.33, p<0.05) and hippocampus (F(3,16)=4.34, p<0.05). This NET down regulation is observed 2 days after discontinuation of chronic Desipramine hydrochloride treatment, a time when plasma and brain concentrations of Desipramine hydrochloride and desmethyldesipramine are undetectable (ie below the 25 ng detection limit of the assay)[2]. |
| Animal Admin | Rats are anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and implanted subcutaneously with osmotic minipumps preloaded with either vehicle (50% saline, 40% DMSO, and 10% ethanol) or Desipramine hydrochloride at a concentration that delivered 5, 10, or 15 mg/kg per day of the free base. Minipumps are removed, under anesthesia, 14 days later. Rats are tested for antidepressant-like behavior in the forced-swim test 2 to 8 days after pump removal and discontinuation of Desipramine hydrochloride treatment. Following the completion of the behavioral tests, rats are killed by decapitation, their brains are removed, and cerebral cortex and hippocampus are dissected for neurochemical analyses[2]. |
| References | [1]. Torres GE, et al. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci. 2003 Jan;4(1):13-25. [2]. Zhao Z, et al. Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine. Neuropsychopharmacology. 2008 Dec;33(13):3190-200. |
Chemical & Physical Properties
| Boiling Point | 407.4ºC at 760 mmHg |
|---|---|
| Melting Point | 214-216ºC |
| Molecular Formula | C18H23ClN2 |
| Molecular Weight | 302.842 |
| Flash Point | 160.5ºC |
| Exact Mass | 302.154968 |
| PSA | 15.27000 |
| LogP | 4.79070 |
| InChIKey | XAEWZDYWZHIUCT-UHFFFAOYSA-N |
| SMILES | CNCCCN1c2ccccc2CCc2ccccc21.Cl |
| Storage condition | 2-8°C |
| Water Solubility | H2O: 50 mg/mL |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 45 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold Vascular - BP lowering not characterized in autonomic section Lungs, Thorax, or Respiration - acute pulmonary edema
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 36 mg/kg/6D-I
- TOXIC EFFECTS :
- Behavioral - somnolence (general depressed activity) Behavioral - hallucinations, distorted perceptions Gastrointestinal - decreased motility or constipation
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 5 mg/kg/5D-I
- TOXIC EFFECTS :
- Behavioral - hallucinations, distorted perceptions Behavioral - toxic psychosis
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 70 mg/kg/4W-I
- TOXIC EFFECTS :
- Behavioral - hallucinations, distorted perceptions Behavioral - toxic psychosis
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - man
- DOSE/DURATION :
- 490 ug/kg
- TOXIC EFFECTS :
- Behavioral - sleep
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Human - woman
- DOSE/DURATION :
- 14 mg/kg/1W-I
- TOXIC EFFECTS :
- Kidney, Ureter, Bladder - urine volume decreased Nutritional and Gross Metabolic - changes in sodium Nutritional and Gross Metabolic - changes in chlorine
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 871 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 55 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 19 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 315 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 88 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 37 mg/kg
- TOXIC EFFECTS :
- Behavioral - convulsions or effect on seizure threshold Behavioral - rigidity (including catalepsy) Nutritional and Gross Metabolic - body temperature decrease
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Mammal - dog
- DOSE/DURATION :
- 25 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LDLo - Lowest published lethal dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - guinea pig
- DOSE/DURATION :
- 55 mg/kg
- TOXIC EFFECTS :
- Cardiac - other changes
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 130 mg/kg
- SEX/DURATION :
- female 10-22 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Newborn - behavioral
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 90 mg/kg
- SEX/DURATION :
- female 9 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - Central Nervous System
- TYPE OF TEST :
- Specific locus test
MUTATION DATA - TEST SYSTEM :
- Insect - not otherwise specified
- DOSE/DURATION :
- 10 gm/L
- REFERENCE :
- JCLBA3 Journal of Cell Biology. (Rockefeller Univ. Press, 1230 York Ave., New York, NY 10003) V.12- 1962- Volume(issue)/page/year: 47,182a,1970 *** REVIEWS *** TOXICOLOGY REVIEW IDPYAK Industrial Pharmacology. (Mount Kisco, NY) V.1-3, 1974-79. Discontinued. Volume(issue)/page/year: 2,209,1975 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5341 No. of Facilities: 62 (estimated) No. of Industries: 1 No. of Occupations: 3 No. of Employees: 1952 (estimated) No. of Female Employees: 1089 (estimated)
- TEST SYSTEM :
- Insect - not otherwise specified
- DOSE/DURATION :
- 10 gm/L
- REFERENCE :
- JCLBA3 Journal of Cell Biology. (Rockefeller Univ. Press, 1230 York Ave., New York, NY 10003) V.12- 1962- Volume(issue)/page/year: 47,182a,1970 *** REVIEWS *** TOXICOLOGY REVIEW IDPYAK Industrial Pharmacology. (Mount Kisco, NY) V.1-3, 1974-79. Discontinued. Volume(issue)/page/year: 2,209,1975 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5341 No. of Facilities: 62 (estimated) No. of Industries: 1 No. of Occupations: 3 No. of Employees: 1952 (estimated) No. of Female Employees: 1089 (estimated)
Safety Information
| Symbol | GHS02, GHS06, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H225-H301 + H311 + H331-H370 |
| Precautionary Statements | P210-P260-P280-P301 + P310-P311 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
| Hazard Codes | Xn: Harmful;F: Flammable;T: Toxic; |
| Risk Phrases | R22;R36/37/38;R42/43;R48/23/24/25;R11 |
| Safety Phrases | S7-S16-S36/37-S45-S26-S24-S22 |
| RIDADR | UN 1230 3/PG 2 |
| WGK Germany | 3 |
| RTECS | HO0525000 |
Articles69
More Articles| Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease. Brain Behav. 3(2) , 75-88, (2013) Cerebral dopamine neurotrophic factor (CDNF) protein has been shown to protect the nigrostriatal dopaminergic pathway when given as intrastriatal infusions in rat and mouse models of Parkinson's disea... | |
| Antidepressants activate the lysophosphatidic acid receptor LPA(1) to induce insulin-like growth factor-I receptor transactivation, stimulation of ERK1/2 signaling and cell proliferation in CHO-K1 fibroblasts. Biochem. Pharmacol. 95 , 311-23, (2015) Different lines of evidence indicate that the lysophosphatidic acid (LPA) receptor LPA1 is involved in neurogenesis, synaptic plasticity and anxiety-related behavior, but little is known on whether th... | |
| Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Neurobiol. Dis. 74 , 295-304, (2015) Long-term administration of l-3,4-dihydroxyphenylalanine (levodopa), the mainstay treatment for Parkinson's disease (PD), is accompanied by fluctuations in its duration of action and motor complicatio... |
Synonyms
| 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N-methyl-, hydrochloride (1:1) |
| T C676 BN&T&J B3M1 &&HCl |
| Desipramine hydrochloride |
| Desimipramine Hydrochloride |
| MFCD00058108 |
| irene |
| 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methylpropan-1-amine,hydrochloride |
| EINECS 200-373-1 |
| 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine hydrochloride (1:1) |
| Desipramine HCl |
| 10,11-Dihydro-N-methyl-5H-dibenz[b,f]azepine-5-propanamine monohydrochloride |
| N-(g-Methylaminopropyl)iminodibenzyl Hydrochloride |
| RMI 9384A |
| 10,11-Dihydro-5-[3-(methylamino)propyl]-5H-dibenz[b,f]azepine hydrochloride |
| 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-aminhydrochlorid |
| N-(γ-Methylaminopropyl)iminodibenzyl hydrochloride |
| 3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methyl-1-propanamine hydrochloride (1:1) |
| DESIPRAMINEHYDROCHLORIDE |
